drugset
drugset / Trial / NCT04120090

Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis

NCT04120090 ↗

Phase 3 Unknown 80 enrolled Beijing Friendship Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aimed to investigate the efficacy and safety of different doses of ruxolitinib as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).

Timeline

Start
2019-07-01
Primary completion
2020-07-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ruxolitinib Small molecule 2.5 mg —
Comparator Ruxolitinib Small molecule 5 mg —
Comparator Ruxolitinib Small molecule 10 mg —
Comparator Ruxolitinib Small molecule 20 mg —

Indications

hemophagocytic syndrome